FDA Names Acting Leaders for Inspections, Tobacco Regulation
US Food and Drug Administration Commissioner Marty Makary named agency veterans to lead tobacco regulation and inspections, two high-profile areas, according to documents seen by Bloomberg.
Elizabeth Miller will serve as the acting associate commissioner for the Office of Inspections and Investigations, and Bret Koplow will be acting director of the Center for Tobacco Products, according to emailed announcements of the appointments. The agency is facing pressure to crack down on illicit e-cigarettes and working to change how it approaches foreign inspections.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
15 minutes ago
- Wall Street Journal
Aerospace Startup JetZero to Start Building Futuristic Planes in North Carolina
Aerospace company JetZero for years has been pitching a spacious, fuel-efficient commercial airplane of the future. Now, the startup is going to actually build it. The Long Beach, Calif.-based company said it would break ground next year on a manufacturing plant in Greensboro, N.C., ultimately investing nearly $5 billion. The factory will employ more than 14,500 workers, the company said, making it North Carolina's largest-ever jobs announcement. It puts JetZero on track to start rolling out its space-age looking, blended-wing airplanes for commercial use by 2032.
Yahoo
24 minutes ago
- Yahoo
Capricor says FDA inspection brought Form 483 with several observations
Capricor Therapeutics (CAPR) announced the completion of the Food and Drug Administration's pre-license inspection of its San Diego manufacturing facility for Deramiocel, the company's lead cell therapy candidate with a biologics license application under FDA review for potential approval in the treatment of Duchenne muscular dystrophy. The inspection concluded with a Form 483 containing several observations. Capricor said it has submitted its responses to the FDA, none of which required material changes to the cGMP process or facility. 'The observations were primarily related to routine quality systems and documentation practices. The Company is confident that the facility will meet the necessary requirements to support product licensure and, pending approval, commercial launch,' Capricor added. The FDA informed Capricor of its intent to hold the Advisory Committee meeting on July 30, although that date is pending confirmation by the FDA. 'At the time of the mid-cycle review, no significant issues or major deficiencies were noted. A late-cycle meeting is planned for mid-July 2025,' the company added. The BLA for Deramiocel remains under priority review with a Prescription Drug User Fee Act action date of August 31. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CAPR: Disclaimer & DisclosureReport an Issue Largest borrow rate increases among liquid names Capricor Therapeutics participates in a conference call with Maxim Capricor Therapeutics Approves 2025 Equity Incentive Plan MongoDB and Asana downgraded: Wall Street's top analyst calls Capricor Therapeutics initiated with a Buy at Roth Capital
Yahoo
39 minutes ago
- Yahoo
Inspira Technologies says ART100 in use at Tier-1 U.S. hospitals
Inspira Technologies (IINN) announced that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation. The ART100 system has been successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months. Details of specific hospital deployments are subject to confidentiality, but reflect Tier-1 facilities in the U.S. This clinical use reflects growing confidence in the system's potential to support patients in critical condition and positions Inspira at the forefront of a rapidly evolving market of life-saving technologies. The consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities. The Company is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on IINN: Disclaimer & DisclosureReport an Issue Inspira Technologies Boosts ART100 Production Amid European Negotiations Inspira Technologies scales up ART100 production capabilities Inspira Technologies initiated with a Buy at Litchfield Hills Inspira Technologies Announces Shareholder Meeting to Address Nasdaq Compliance Inspira Technologies Launches Global Rollout of ART100 System Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
